Asthma is considered “severe” when it is uncontrolled despite the best-suited treatment being used correctly and diligently, and any factor that may contribute to the Asthma is managed, or Asthma that worsens when high dose treatment is decreased 24
Eosinophilic Asthma is caused by an increased number of eosinophils. Eosinophils are a specific type of white blood cell (making up about 5 % of all white blood cells) which help us fight off infections, and are therefore an important part of our immune system. 25,26
The condition is generally very severe and seen in people who developed Asthma as adults, but it may very seldomly be seen in children or teenagers. 26
Eosinophilic Asthma is very similar in many ways to allergic Asthma, but it differs from allergic Asthma in that those who struggle with Eosinophilic Asthma do not necessarily experience a trigger from an allergen (such as pollen, pet dander or smoke), and they often struggle with chronic sinusitis or nasal polyps. 26
Of all asthmatics, 1 in 3 may have Eosinophilic Asthma. 27
It is possible to live well with Asthma if you manage it.
To test for Eosinophilic Asthma, your healthcare provider will send either blood or sputum to a laboratory to test for eosinophils. 28
The above tests, as well as confirmation of certain biomarkers, can indicate what type of Asthma a person has, as well as what type of treatment would probably be most effective. 29
Patients with severe Eosinophilic Asthma are usually treated with the same treatment as those with less severe allergic Asthma, which are inhaled bronchodilators and/or corticosteroids. Unfortunately, these may not be completely effective to manage severe Eosinophilic Asthma. 28
Newer biologic therapies, called monoclonal antibodies, are more individualised treatment prescribed to help manage this condition. They work on different targets or biomarkers in the body, which makes the diagnosis tests very important. 24
Biologics have been proven to: 24
Improve control of Asthma (as measured by the Asthma Control Test)
Follow us for more:
Social media, review sites and other public internet sites are not the places for your comments and questions, however questions or comments can be answered by the AZ Medical Information Service at the adverse events link. AstraZeneca Pharmaceuticals (Pty) Ltd. South Africa Reg. No. 1992/005854/07 Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191, South Africa. Private Bag X23, Bryanston, 2021, South Africa. Tel: 011 797-6000. www.astrazeneca.com Activity ID: ZA-6088. Expiry date: 30 April 2027.
Dear All,
Please be informed that AstraZeneca has become aware of illegitimate groups on social media platforms—including Instagram, WhatsApp, and Facebook—operating an illegal Ponzi scheme falsely claiming association with AstraZeneca. These schemes have no connection to AstraZeneca and are unlawfully using the AstraZeneca name and a fake bank account.
AstraZeneca is taking legal action to stop these activities.
We strongly advise you not to pay any fees or share any personal information with these groups, as they are entirely unaffiliated with AstraZeneca or its products.
Thank you for your attention.
AstraZeneca Pharmaceuticals (Pty) Ltd. South Africa Reg. No. 1992/005854/07
Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191, South Africa.
Private Bag X23, Bryanston, 2021, South Africa.
Tel: 011 797-6000. www.astrazeneca.com
Expiry date: 31 December 2025. Activity ID: ZA-6140.
Legal Notice and Terms | Cookies | Privacy Notice | Adverse Event Reporting